13 employees
NsGene develops products for the treatment of neurological, alzheimer’s, and parkinson's disease and sensorineural hearing loss.
1999
$5.1M
from 3 investors over 3 rounds
NsGene A/S raised $5.1M on May 2, 2005
Investors: LD Fonde, Vækstfonden and Karolinska Development